As per MRFR analysis, the Pleurisy Market Size was estimated at 0.53 (USD Billion) in 2023.The Pleurisy Market Industry is expected to grow from 0.56(USD Billion) in 2024 to 1.2 (USD Billion) by 2035. The Pleurisy Market CAGR (growth rate) is expected to be around 7.11% during the forecast period (2025 - 2035)
The Global Pleurisy Market is undergoing notable shifts, primarily influenced by the rising cases of respiratory disorders and the increased recognition of pleurisy within the medical community and the patient population. There is an increase in the number of pleurisy cases as respiratory diseases such as pneumonia and tuberculosis are increasing globally, which increases the demand for diagnosis and treatment. The government and other healthcare organizations as well as private healthcare providers are trying to improve the level of healthcare services which further facilitates market growth. In addition, the evolution of medical technology is creating further opportunities through new diagnostic devices and treatment methods that can be used.
Telemedicine has become widely accepted because it enables patients to get timely consultations which helps specialists manage pleurisy cases. This is especially true for areas that do not have adequate healthcare facilities. Recently, greater focus has been directed towards understanding the very causes of pleurisy from a healthcare industry perspective. Businesses are now funding clinical trials aimed at developing more effective relief and treatment therapies. In addition, international healthcare institutions are advocating for the shift towards more comprehensive approaches to care delivery, focusing on integrated management of pleurisy and its comorbid conditions. This shift also provides additional opportunities for other market participants. All these factors taken together is considered to have a beneficial impact on the level of innovation and increase the efficiency with which patients are treated in the Global Pleurisy Market region.
The rising prevalence of respiratory disorders globally is a significant driver for the Global Pleurisy Market Industry. According to the World Health Organization, respiratory diseases accounted for 3 million deaths worldwide in the past year, showing a steady increase attributed to factors such as pollution, smoking, and urbanization. Various established health organizations, including the American Lung Association, report that chronic respiratory diseases, including conditions leading to pleurisy, have surged in recent years due to environmental degradation and lifestyle choices.As a result, the demand for medical treatments and diagnostic modalities aimed at managing pleurisy is expected to climb continuously, thereby propelling the growth of the Global Pleurisy Market.
The introduction of advanced diagnostic tools and imaging technologies is driving growth in the Global Pleurisy Market Industry. Innovations such as high-resolution computed tomography (HRCT) scans and ultrasound imaging have significantly enhanced the early detection and diagnosis of pleurisy. Established medical institutions, including the Medical Imaging and Technology Alliance, highlight that advancements in imaging technologies can improve diagnostic accuracy by up to 40%, which can lead to timely interventions.This increased accuracy encourages healthcare practitioners to refer patients for testing and treatment sooner, contributing to the market's expansion on a global scale.
There is a growing awareness about pleurisy and related respiratory conditions, driven by global health campaigns and education programs. Organizations like the Global Initiative for Chronic Obstructive Lung Disease have been instrumental in raising awareness about lung health. Data indicates that awareness campaigns have led to a 25% increase in patients seeking medical advice for respiratory symptoms within the last two years. This can be attributed to both social media outreach and grassroot efforts, resulting in healthcare providers seeing a higher volume of patients with pleurisy.This further supports growth in the Global Pleurisy Market.
The aging population is a significant factor impacting the growth trajectory of the Global Pleurisy Market Industry. The United Nations reported that by 2030, nearly 1 in 6 people will be aged 60 years or older, increasing the likelihood of chronic diseases including pleurisy. As the population ages, there is a heightened incidence of diseases that complicate respiratory health. Aging increases susceptibility to infections and other lung-related issues, which boosts the demand for pleurisy treatment options.Moreover, healthcare systems worldwide are adapting to accommodate this demographic shift, which will likely enhance the market for treatments and interventions related to pleurisy.
The Global Pleurisy Market is categorized into several types, with key segments including Acute Pleurisy, Chronic Pleurisy, and Recurrent Pleurisy, which hold notable market valuation and growth potential. The market valuation of 0.56 USD Billion in the year 2024, and this is projected to grow to 1.2 USD Billion by 2035. Among these segments, Acute Pleurisy stands out as a dominant force, with a market value of 0.25 USD Billion in 2024, doubling to 0.5 USD Billion by 2035, reflecting its impact and relevance in healthcare that often requires immediate intervention due to its sudden onset.Chronic Pleurisy, valued at 0.18 USD Billion in 2024 and expected to reach 0.36 USD Billion by 2035, is significant as it addresses ongoing respiratory issues, indicative of its longer treatment necessity which contributes to higher healthcare expenditure over time.
Finally, Recurrent Pleurisy, while comparatively smaller, with a valuation of 0.13 USD Billion in 2024 projected to grow significantly to 0.34 USD Billion by 2035, signifies the recurring nature of pleurisy in some individuals, thereby elevating the necessity for continuous management and monitoring within the healthcare system.The dominance of Acute Pleurisy demonstrates both the market's response to immediate medical needs and the evolving understanding of respiratory conditions. Furthermore, the overall Global Pleurisy Market dynamics suggest that the increasing prevalence of respiratory diseases, evolving treatment methods, and heightened awareness surrounding pleurisy are driving overall market growth.
Each type plays a unique role: Acute Pleurisy commands a major share due to its urgency and acute onset, while Chronic and Recurrent Pleurisy highlight the extensive implications of long-term health management and healthcare resource allocation.The insights into these types in the Global Pleurisy Market data reveal critical trends in patient care and treatment pathways that healthcare providers must navigate, offering significant opportunities for pharmaceutical and healthcare industries to innovate and expand their offerings across these segments.
The Global Pleurisy Market is witnessing significant growth, primarily driven by advancements in various Diagnosis Methods. In 2024, the overall market was valued at 0.56 billion USD, climbing to 1.2 billion USD by 2035, showcasing a robust trajectory. Diagnosis methods in this market encompass Physical Examination, Imaging Tests, and Laboratory Tests, each serving critical roles. Physical examination remains crucial for preliminary assessments, allowing healthcare providers to identify potential pleurisy symptoms early. Imaging tests, including X-rays and CT scans, dominate in providing accurate visual representations of the lungs and pleura, thereby facilitating effective diagnosis and treatment planning.
Laboratory tests play a significant role in determining underlying causes through pleural fluid analysis, helping in evaluating infections and other conditionsmaking these tests indispensable in managing pleurisy. The growing prevalence of respiratory diseases and advancements in diagnostic technology further contribute to the increasing adoption of these techniques. The Global Pleurisy Market statistics highlight a compounding market growth, emphasizing the need for efficient diagnosis in improving patient outcomes.
The Global Pleurisy Market, valued at 0.56 USD Billion in 2024, showcases a diverse array of Treatment Type options for patients suffering from this condition. The market has been segmented into three primary categories: Medication, Surgical Procedures, and Therapeutic Procedures. Medication plays a critical role for symptomatic relief and management of underlying causes, and it is one of the most widely sought-after treatment options. Surgical Procedures, while typically reserved for severe cases, are essential due to their potential to directly address the source of pleurisy.Therapeutic Procedures, which may include interventions like drainage of pleural effusions, significantly aid in relieving symptoms and improving patient quality of life.
The growing incidence of respiratory diseases and associated pleuritic complications is expected to drive significant market growth. With the Global Pleurisy Market statistics indicating an overall increase in demand for these treatments, there is a tangible opportunity for advancements in Medication, which dominates the market space due to continuous pharmaceutical innovations.Additionally, effective public health campaigns emphasizing awareness about pleural diseases support the growth of this market segment by promoting timely medical intervention.
The Global Pleurisy Market serves several key End User categories, primarily encompassing Hospitals, Clinics, and Home Care, which collectively fulfill the rising demand for effective pleurisy management. In 2024, the market was valued at 0.56 USD Billion, reflecting a growing emphasis on healthcare solutions across various settings. Hospitals are significant players in this landscape, delivering immediate and specialized care for pleurisy patients, which is essential given the complexity of the condition. Clinics also contribute meaningfully by providing primary care and outpatient services, acting as the first point of contact for patients.
Home Care has been increasingly recognized due to its role in enhancing patient comfort and enabling treatment in a familiar environment, which is particularly important for chronic conditions like pleurisy. The transition towards home care services is driven by a global shift in healthcare towards patient-centric models, creating opportunities for product innovation and improving treatment adherence. Collectively, the Global Pleurisy Market segmentation across these End User categories demonstrates robust growth potential, marked by evolving healthcare strategies and patient preferences.
The Global Pleurisy Market displays significant regional variations, with the market valued at 0.56 USD Billion in 2024 and projected to grow by 2035. North America holds the majority share, being valued at 0.25 USD Billion in 2024 and expected to reach 0.52 USD Billion by 2035. This region's prominence is largely due to advanced healthcare systems and higher prevalence rates of respiratory conditions. Europe follows with a market value of 0.15 USD Billion in 2024, poised to grow to 0.3 USD Billion in 2035, driven by an aging population and favorable policies towards chronic disease management.The Asia-Pacific (APAC) region, valued at 0.1 USD Billion in 2024, is anticipated to expand to 0.25 USD Billion as healthcare infrastructure improves and awareness increases.
In contrast, South America and the Middle East and Africa (MEA) remain in smaller markets, valued at 0.03 USD Billion and 0.03 USD Billion in 2024, respectively, with potential growth to 0.07 USD Billion and 0.06 USD Billion by 2035. The slower growth in these regions can be attributed to limited healthcare access and awareness. Overall, these regional dynamics highlight the diverse factors influencing the Global Pleurisy Market and illustrate opportunities for targeted interventions and investment.
The Global Pleurisy Market has been experiencing a dynamic shift due to various factors including advancements in diagnostic techniques and therapeutic options available for patients. With a growing prevalence of pleural diseases and an increasing awareness about respiratory health, the competitive landscape is becoming more intricate as companies seek to position themselves effectively. Key players are focusing on innovation and expanding their product offerings to cater to unmet needs in the market. The race to enhance patient outcomes has triggered collaboration between pharmaceutical companies and healthcare professionals, while market analysis indicates a trend towards personalized medicine in treating conditions associated with pleurisy.
This wave of evolution is likely fostering competitive strategies within the market, leading to a rich environment for new entrants as well as established firms aiming to bolster their market share.Pfizer has established a solid presence in the Global Pleurisy Market through its portfolio of treatments that address respiratory conditions. Known for its commitment to research and development, Pfizer leverages its extensive resources to create innovative therapies aimed at managing pleurisy and associated pleural diseases. The company’s strengths stem from its robust clinical trial capabilities and established relationships with healthcare providers, allowing it to effectively understand patient needs and market demands. Pfizer also has an expansive distribution network that facilitates accessibility to its products across various regions, enabling it to maintain a competitive edge by ensuring that its therapies are readily available to those who require them.
The company’s focus on enhancing patient support programs further solidifies its reputation as a leader in the respiratory health sector.Merck and Co has also made significant strides in the Global Pleurisy Market, primarily through a range of pharmaceutical products aimed at treating respiratory diseases. The company is known for its comprehensive pipeline that includes both patented and generic drugs, reflecting its diverse approach to addressing pleurisy. Merck and Co's market presence is strengthened by its strategic mergers and acquisitions, which have broadened its capabilities and product offerings.
The company invests heavily in research to develop new treatments that are not only effective but also improve patients' quality of life. Its strong emphasis on partnerships and collaborations with healthcare institutions further enhances its market position, enabling the company to effectively deliver innovative solutions. With a focus on clinical advancements and a commitment to patient-centered care, Merck and Co continues to be a prominent player in the Global Pleurisy Market.
Recent developments in the Global Pleurisy Market have been influenced significantly by advancements in pharmaceutical companies. In September 2023, AbbVie announced positive results from clinical trials for its new pleurisy treatment, potentially enhancing its market position. Pfizer has invested heavily in Research and Development initiatives focused on pleurisy-related therapies, aiming to improve patient outcomes. Meanwhile, Merck and Co. has been collaborating with various healthcare institutions to drive awareness and education regarding pleurisy management options.In terms of mergers and acquisitions, no significant activity has been reported impacting the companies of interest, such as Roche, Gilead Sciences, and AstraZeneca, within recent months.
Nonetheless, the cumulative valuation of these companies has shown an upward trend due to increasing global healthcare spending and the rising incidence of pleurisy conditions, which collectively elevate the demand for effective treatment solutions. Additionally, notable developments in the regulatory landscape, particularly in North America and Europe, have prompted further investments in the Global Pleurisy Market, encouraging innovation that could benefit patient care. Over the last two years, the focus on personalized medicine in pleurisy treatment has gained traction, reflecting a shift towards more tailored healthcare solutions for affected patients.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 0.53(USD Billion) |
| MARKET SIZE 2024 | 0.56(USD Billion) |
| MARKET SIZE 2035 | 1.2(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.11% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Pfizer, Merck and Co, Roche, Gilead Sciences, AbbVie, Johnson and Johnson, Teva Pharmaceutical Industries, Novartis, BristolMyers Squibb, AstraZeneca, GlaxoSmithKline, Amgen, Eli Lilly and Company, Sanofi |
| SEGMENTS COVERED | Type, Diagnosis Method, Treatment Type, End User, Regional |
| KEY MARKET OPPORTUNITIES | Rising prevalence of pleurisy, Advancements in diagnostic tools, Increasing investment in research, Development of targeted therapies, Growing awareness and education programs. |
| KEY MARKET DYNAMICS | Increasing prevalence of respiratory diseases, Growing demand for diagnostic imaging, Advancements in treatment options, Rising awareness of pleurisy symptoms, Improvements in healthcare infrastructure |
| COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
Pleurisy Market Highlights:
Frequently Asked Questions (FAQ) :
The Global Pleurisy Market is expected to be valued at 0.56 USD Billion in 2024.
In 2035, the Global Pleurisy Market is projected to reach a value of 1.2 USD Billion.
The expected CAGR for the Global Pleurisy Market from 2025 to 2035 is 7.11%.
North America is expected to hold the largest market share, valued at 0.25 USD Billion in 2024.
The market value for acute pleurisy is projected to be 0.5 USD Billion in 2035.
Major players in the market include Pfizer, Merck and Co, Roche, Gilead Sciences, and AbbVie.
The market size for chronic pleurisy is expected to double to 0.36 USD Billion by 2035.
The Asia-Pacific region is projected to reach a market value of 0.25 USD Billion in 2035.
Market challenges may arise from competition, regulatory changes, and evolving patient needs.
The expected market value for recurrent pleurisy in 2024 is 0.13 USD Billion.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
